Daniel Weber

Chairman of the Board of Directors

Daniel is the General Manager of Boehringer Ingelheim Switzerland. He got his training in Business Administration at the University of St. Gallen. His international career with Roche, Novartis and Boehringer took him to six countries including many years in the US. His experience covers a wide range of commercial positions at country and corporate level. He is married, has two adult children, a dog and loves sports.

Karl Penz, MBA

Member of the Board of Directors

Karl Penz is the Head of Finance – Innovation Unit (R&D) & Group Functions of Boehringer Ingelheim.

Karl leads global teams with his broad experience in Finance & Controlling matters as well as large scale program management. He brings along excellent analytical ability and interpersonal skills, and a sharp understanding of industry. He is driving change and engages others in shaping the future of Boehringer Ingelheim.

Lamine Mbow, PhD

Member of the Board of Directors

Lamine gained his PhD in immunology at the University of Neuchâtel, Switzerland, followed by postdoctoral training in host immunity at the CDC Fort Collins, CO and Colorado State University, CO in the US. He has over 20 years experience in drug discovery in various fields including immunology, inflammation, infectious diseases, vaccines and cancer immunobiology. Lamine led small biotech oragnisations as CSO and held several positions in the pharmaceutical industry (Centocor (J&J), Novartis and Boehringer Ingelheim). Ha authored and co-authored more than 60 publications including top tiered journals.

Simon J. Ittig, PhD

Member of the Board of Directors and Chief Executive Officer

Simon completed a PhD on microbial pathogenesis at the University of Basel in the framework of the Werner Siemens Excellence fellowships. He started working on the T3 Pharma technology during his postdoctoral studies at the Biozentrum. For these achievements he received the Novartis and University of Basel Excellence Scholarship in 2014 and a research prize from the Huggenberger-Bischoff foundation for cancer research in the same year.